Home » Stocks » TFFP

TFF Pharmaceuticals, Inc. (TFFP)

Stock Price: $19.35 USD 1.68 (9.51%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $20.95 +1.60 (8.27%) Jan 19, 6:32 PM
Market Cap 392.74M
Revenue (ttm) n/a
Net Income (ttm) -41.37M
Shares Out 20.87M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $19.35
Previous Close $17.67
Change ($) 1.68
Change (%) 9.51%
Day's Open 17.75
Day's Range 17.60 - 21.14
Day's Volume 801,909
52-Week Range 3.51 - 21.14

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals to present at H.C. Wainwright Virtual BioConnect 2021 Conference, with a corporate presentation available on January 11, 6AM ET.

Business Wire - 1 month ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces first dosing of asthma patients with Voriconazole Inhalation Powder in a Ph.1b clinical trial for the treatment of IPA.

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)-- #Jefferies--TFF Pharmaceuticals to present at the Jefferies Virtual London Healthcare Conference, with a corporate presentation on November 19, at 2:55 PM ET.

Seeking Alpha - 2 months ago

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals reports third quarter 2020 financial and business results - Conference call today, Thursday, November 5, 2020 at 4:30pm ET

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals and Felix Biotechnology sign Letter of Intent for a Collaboration, Development and License Agreement for bacteriophage therapies.

Business Wire - 2 months ago

AUSTIN, Texas & MENLO PARK, Calif.--(BUSINESS WIRE)--TFF Pharmaceuticals and Augmenta Bioworks enter into a worldwide joint development agreement for COVID-19 monoclonal antibody therapies.

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces third quarter 2020 financial results and business update conference call on November 5, 2020.

Seeking Alpha - 2 months ago

TFF possess the rights to a game-changing drug formulation technology. They have a cost-efficient, fast route to market for their improved drugs.

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces positive preclinical results with University of Georgia universal influenza vaccines.

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals expands its cGMP manufacturing capabilities with Experic by installing a Thin Film Freezing processing line.

Business Wire - 2 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals updates progress of human clinical trial with Tacrolimus Inhalation Powder for prevention of lung transplant rejection.

Business Wire - 3 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces results of its 2020 Annual Meeting of Stockholders

Business Wire - 3 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals comments on animal studies in the development of high potency remdesivir as a dry powder for inhalation by Thin Film Freezing.

Business Wire - 4 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals (NASDAQ: TFFP) announces topline results of Voriconazole Inhalation Powder Phase 1 clinical trial.

Business Wire - 4 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals to participate in Anti-fungal Webinar presented by Maxim Group LLC on September 17th, 2020

Business Wire - 4 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) will present at the H.C.

Zacks Investment Research - 4 months ago

With Wall Street set to see its best August in 36 years on coronavirus cure optimism, Fed's plan to keep rates low and upbeat consumer confidence put spotlight on stocks with best month-to-dat...

Other stocks mentioned: BMCH, CRM, LOB, LQDT
Seeking Alpha - 4 months ago

TFF Pharmaceuticals: Undervalued Novel Drug Manufacturing Technique

Benzinga - 5 months ago

TFF Pharmaceuticals (NASDAQ: TFFP) shares are trading higher after the company on Thursday reported a global licensing deal with UNION therapeutics for its Thin Film Freezing technology in com...

Seeking Alpha - 5 months ago

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

HELLERUP, Denmark, Aug. 13, 2020 /PRNewswire/ -- Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has advanc...

Business Wire - 5 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals in worldwide licensing agreement with UNION therapeutics for its Thin Film Freezing technology in combination with niclosamide.

Business Wire - 5 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals (NASDAQ:TFFP) reports second quarter 2020 financial and business results - Conference call today at 4:30 PM ET

Business Wire - 5 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), announces $25.9 million in private financing to further advance its Thin Film Freezing technology platform.

Business Wire - 5 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), it will release its second quarter 2020 financial results on August 13, 2020 at 4:00 PM ET.

Business Wire - 5 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announces completion of dosing for Voriconazole Inhalation Powder Phase 1 clinical trial.

Business Wire - 5 months ago

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals Comments on Research on the Re-formulation of Remdesivir to a Dry Powder Form for COVID-19 Antiviral Treatment

Seeking Alpha - 8 months ago

TFF Pharmaceuticals' (TFFP) CEO Glenn Mattes on Q1 2020 Results - Earnings Call Transcript

About TFFP

TFF Pharmaceuticals, an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company has a research collaboration with the University of Georgia's Center for Vaccines and Immunology (CVI), along with the University of Texas at Austin (UT Austin), to evaluate the immunogenicity of universal influenza... [Read more...]

Industry
Biotechnology
IPO Date
Oct 25, 2019
CEO
Glenn R. Mattes
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
TFFP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TFFP stock is "Buy." The 12-month stock price forecast is 25.67, which is an increase of 32.66% from the latest price.

Price Target
$25.67
(32.66% upside)
Analyst Consensus: Buy